摘要
鼠双微体4(MDM4)作为MDM家族中的一员,是一个由p53负调节的新兴的重要致癌基因。肿瘤抑制蛋白p53在细胞周期停滞、细胞凋亡与平衡中起着至关重要的作用。据报道,在众多的人类癌症,包括血液系统恶性肿瘤已发现p53频繁失活现象。MDM4,新发现的p53蛋白调节器,经常在各种实体肿瘤如皮肤黑色素瘤,视网膜母细胞瘤和血液系统恶性肿瘤(慢性淋巴细胞白血病,急性髓细胞白血病和套细胞淋巴瘤)中放大。多数证据表明, MDM4过度表达与肿瘤发展和预后不良相关,肿瘤发展和预后不良可通过敲除MDM4的表达或恢复p53功能逆转,并支持未来MDM4特异性疗法设计的基本原理。本文讨论并着重运用MDM4作为一种新的生物标志物以及血液系统恶性肿瘤的治疗目标。
关键词: 生物标志物,血液系统恶性肿瘤,MDM2,MDM4,p53,治疗方法。
图形摘要
Current Cancer Drug Targets
Title:Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Volume: 15 Issue: 9
Author(s): Lei Cao, Lei Fan and Jian-Yong Li
Affiliation:
关键词: 生物标志物,血液系统恶性肿瘤,MDM2,MDM4,p53,治疗方法。
摘要: Mouse double minute 4 (MDM4) as a member of MDM family, is an oncogene emerging as an imperative negative regulator of p53. Tumor suppressor protein p53 plays a crucial role in cell cycle arrest, apoptosis and homeostasis. It has been reported that frequent inactivation of p53 was observed in numerous human cancers including hematologic malignancies. MDM4, the newly discovered modulator of p53 protein, is frequently amplified in various solid tumors such as cutaneous melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic leukemia, acute myeloid leukemia and mantle cell lymphoma. Multiple evidences implicate that over-expression of MDM4 is associated with tumor progression and poor prognosis which can be reversed by knockdown of MDM4 expression or restoration of p53 function, and support the rationale for the design of future MDM4-specific therapeutics. This article discusses and focuses on using MDM4 as a novel biomarker as well as a therapeutic target for hematologic malignancies.
Export Options
About this article
Cite this article as:
Lei Cao, Lei Fan and Jian-Yong Li , Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies, Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/156800961509151110124616
DOI https://dx.doi.org/10.2174/156800961509151110124616 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Current Chemical Biology Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets The Upshot of PI3K Inhibitors as Anticancer Arsenal: A Short Review
Current Bioactive Compounds Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research
Current Stem Cell Research & Therapy MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Current Topics in Medicinal Chemistry Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Advances in HTLV-1 Peptide Vaccines and Therapeutics
Current Protein & Peptide Science Editorial (Thematic Issue: Helicobacter pylori Eradication Therapy: Advantages and Disadvantages)
Current Pharmaceutical Design Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets